Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss.
about
Recent advancements in multimodality treatment of gliomasOligodendroglioma: pathology, molecular mechanisms and markersImmunoFISH is a reliable technique for the assessment of 1p and 19q status in oligodendrogliomasReview: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapiesMicrosatellite alteration in multiple primary lung cancer.Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markersClinicopathologic features of pediatric oligodendrogliomas: a series of 50 patientsThe importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction-based microsatellite loss of heterozygosity analysis of oligodendrogliomas.Automated Analysis of 1p/19q Status by FISH in Oligodendroglial Tumors: Rationale and Proposal of an Algorithm.How molecular testing can help (and hurt) in the workup of gliomas.Emerging insights into the molecular and cellular basis of glioblastoma.Contribution of 1p, 19q, 9p and 10q Automated Analysis by FISH to the Diagnosis and Prognosis of Oligodendroglial Tumors According to WHO 2016 Guidelines.A "weighted" fluorescence in situ hybridization strengthens the favorable prognostic value of 1p/19q codeletion in pure and mixed oligodendroglial tumors.Co-polysomy of chromosome 1q and 19p predicts worse prognosis in 1p/19q codeleted oligodendroglial tumors: FISH analysis of 148 consecutive cases.Correlation of histomorphologic prognostic markers and proliferative index with loss of heterozygosity 1p/19q and MGMT status in diffusely infiltrating gliomas.Short-term survivors in glioblastomas with oligodendroglioma component: a clinical study of 186 Chinese patients from a single institution.HER2 expression identifies dynamic functional states within circulating breast cancer cells.Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting.Loss of heterozygosity analysis in malignant gliomas.Molecular diagnostics: techniques and recommendations for 1p/19q assessment.1q/19p co-polysomy predicts longer survival in patients with astrocytic gliomas.Something old and something new about molecular diagnostics in gliomas.Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors.DNA hypermethylation and 1p Loss silence NHE-1 in oligodendroglioma.1p/19q-driven prognostic molecular classification for high-grade oligodendroglial tumors.Application of brush cytology for FISH-based detection of 1p/19q codeletion in oligodendroglial tumors.Polysomy of chromosomes 1 and 19: an underestimated prognostic factor in oligodendroglial tumors.MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors.Prognostic significance of relative 1p/19q codeletion in oligodendroglial tumors.
P2860
Q27001724-F8DCD6D9-3982-4376-A893-6F4B16C3CF21Q27002448-F24CDE76-BA5F-4F33-BAD9-9F56816DE6A5Q33784207-B9699CAB-9713-45B7-A1BD-C4E640D1A532Q33925544-256B6819-9009-4E88-A8CE-76710FDB6453Q34430522-3E183C12-EB4D-4C20-8D51-8A36EB2A15EAQ34815207-8235E53F-90E7-498A-9E72-71B8F25B827AQ35067733-5496C895-F47E-4E18-8FD6-BD94D4AEED3AQ35634042-6891290B-3B66-4FA4-92E0-8F6E27F12BBAQ35681251-BCF2FB7A-B6FC-41F9-B868-B3DBEB1F9E57Q35770275-02413A65-E8B8-4A10-9444-4CA80D125E50Q35914897-D6924B85-389E-4D55-A5FB-6D21F34F3114Q36234884-DDBA1048-0984-4063-A065-BB8B7FC4AA1BQ36919406-81EB56CE-C8F5-4D43-89C1-67CAFF63B0E7Q37109261-F38348D3-E0F5-405D-941D-5E15A60D2DE7Q37390680-AE90DFCC-B503-4FD4-ADAA-6BC864F70985Q37471678-A684C217-ACF2-40A9-8359-233303D05E31Q37510512-69C1BE93-8BF4-4213-B95E-8DDC6F78B857Q37641248-1100DB01-B57A-4C5C-914E-E34F7B48FC23Q37858468-D87DCDF7-8A95-4105-95B7-2899C8A69F06Q37883145-50F5E449-FD17-414C-A154-8F5A9EB6E766Q38627124-D364DF5E-5687-46E4-AD63-9FB7B752416CQ42366532-B04E4552-ABD0-482A-AFB5-0E85AB49A35DQ43238974-0EBD6615-8DB4-4A4A-BD4E-B7D9F6D42531Q43442484-E4D49D65-E648-445A-95C7-ECC24227A994Q48465762-5DB92C48-8971-4705-9EAC-5B6A89985E40Q48588128-956A2A4E-B02E-47AF-B9BA-90810C2411D1Q48626706-3F763E27-4063-4404-B210-4607B8CCCE25Q48668623-352796A3-0344-489B-99D7-EBB329C7AE6EQ48686096-7CCF6766-6687-4860-94EE-A7473F7DBA75Q50977877-E457AE2A-B5BC-49D5-B071-27E725EDD982Q52149937-D17A8A40-2734-46D5-8FE2-6B3E3B3BC7E8
P2860
Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Polysomy for chromosomes 1 and ...... s with concurrent 1p/19q loss.
@ast
Polysomy for chromosomes 1 and ...... s with concurrent 1p/19q loss.
@en
type
label
Polysomy for chromosomes 1 and ...... s with concurrent 1p/19q loss.
@ast
Polysomy for chromosomes 1 and ...... s with concurrent 1p/19q loss.
@en
prefLabel
Polysomy for chromosomes 1 and ...... s with concurrent 1p/19q loss.
@ast
Polysomy for chromosomes 1 and ...... s with concurrent 1p/19q loss.
@en
P2093
P2860
P1476
Polysomy for chromosomes 1 and ...... as with concurrent 1p/19q loss
@en
P2093
A John Iafrate
April F Eichler
Azra H Ligon
David N Louis
Keith L Ligon
Michael Silver
Patrick Y Wen
Quynh U Vu
Rebecca A Betensky
P2860
P304
P356
10.1158/1078-0432.CCR-09-0867
P407
P577
2009-10-06T00:00:00Z